Entities / Company
Certara (United States).
company in St Louis, United States
- Reports this week
- 0
- Active events
- 0
- Connections
- 47
What's happening
One to three months ago
Gone quiet
No new reports in 90+ days-
Certara developed and utilized the Simcyp Simulator platform, which the EMA qualified for regulatory submissions, marking a successful collaboration.Some support1 report
-
Certara and Merck announced an expansion of their clinical technology collaboration, which began on July 8, 2025.Speculative1 report
-
MSD and Certara expanded their collaboration to utilize Pinnacle 21 software.Speculative1 report
-
The FDA announced a phaseout of animal testing, a move involving Certara and referencing the background of a CEO formerly with DuPont.Some support2 reports
-
Certara operates within the Biomedical and Genetics industry.Some support1 report
-
Zacks ranks Certara in Medical - Biomedical and Genetics industry. Matras discusses high-powered approaches to close winners.Some support1 report
-
Christopher Bouton was appointed CTO of Certara to advance AI drug discovery, following Certara's acquisition of Vyasa in 2022.Some support1 report
-
Certara reported low Return on Equity (ROE) and lower net income growth compared to the industry average in August 2025.Some support1 report
-
William F Feehery was appointed Chief Executive Officer of Certara.Some support1 report
-
Certara saw 11% stock price growth on NASDAQ, coinciding with discussions on AI's role in healthcare.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Certara (United States) this week
News at the entities that move Certara (United States) most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Certara (United States)
Connections
The 2 strongest of 47, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.History
Events by the month they beganJune 2026
11 events- Certara's performance was compared against the growth of the healthcare services industry.
- Certara developed and utilized the Simcyp Simulator platform, which the EMA qualified for regulatory submissions, marking a successful collaboration.
- Certara and Merck announced an expansion of their clinical technology collaboration, which began on July 8, 2025.
- MSD and Certara expanded their collaboration to utilize Pinnacle 21 software.
- The FDA announced a phaseout of animal testing, a move involving Certara and referencing the background of a CEO formerly with DuPont.
- Certara operates within the Biomedical and Genetics industry.
- Zacks ranks Certara in Medical - Biomedical and Genetics industry. Matras discusses high-powered approaches to close winners.
- Christopher Bouton was appointed CTO of Certara to advance AI drug discovery, following Certara's acquisition of Vyasa in 2022.
- Certara reported low Return on Equity (ROE) and lower net income growth compared to the industry average in August 2025.
- William F Feehery was appointed Chief Executive Officer of Certara.
- Certara saw 11% stock price growth on NASDAQ, coinciding with discussions on AI's role in healthcare.